病理调解了轻度认知障碍患者的血生物标志物和认知功能
Lu Zhao1, Qi Qiu1, Shaowei Zhang1
1Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University of Medicine, Shanghai, China.
Experimental gerontology
|August 11, 2024
概括
血GFAP和NfL生物标志物与TAU PET成像和阿尔茨海默病的认知衰退相关. 特定大脑区域的陶氏病理介绍了这些生物标志物与认知障碍之间的联系.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
- 神经成像是一种神经成像.
背景情况:
- 状纤维酸蛋白 (GFAP) 和神经丝光 (NfL) 是神经炎症和神经退行症的关键非粉样生物标志物.
- 了解它们与病理和认知功能的关系对于早期诊断和治疗认知衰退至关重要.
研究的目的:
- 调查血GFAP和NfL水平与F-AV-1451PET成像之间的关联.
- 探索这些生物标志物和区域沉积对认知功能的影响.
- 研究病理在血生物标志物与认知衰退之间的关系中的调解作用.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 和上海预防老年痴呆症行动 (SHAPE) 队列的数据.
- 收集了用于GFAP和NfL测量的血样本,进行了F-AV-1451PET扫描,并进行了认知评估.
- 采用机器学习模型 (LASSO) 来区分认知正常 (CN) 和轻度认知障碍 (MCI) 个体,使用血生物标志物和PET成像数据.
主要成果:
- 血生物标志物 (GFAP,NfL) 和区域性tau PET SUVR (杏仁体,内腔皮层) 的组合有效地将MCI与CN个体区分开来 (AUC 0.783-0.926).
- 认知功能与血GFAP/NfL水平和桃体和左脑内皮层的沉积有负相关性.
- 这些大脑区域的沉积增加与血GFAP和NFL水平的升高有关,病理介于对认知衰退的影响.
结论:
- 血GFAP和NfL是有价值的非粉样蛋白生物标志物,与MCI中的区域沉积和认知功能有关.
- 杏仁体和脑内皮层中的tau病理在血生物标志物和认知衰退之间的关系中起着调解作用.
- 这些发现突显了病理的意义,并表明了血生物标志物的潜力,用于监测神经退行过程.
相关概念视频
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:30Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
112
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
112